看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。5 }5 d) \; ^. j
& s# ^9 L! {! o* [* G6 J" g
6 y: Y2 r$ P. T+ i/ x5 R* ZCurrently available feasibility data for possible combination strategies. ! _4 ]3 w! \7 A
————————————————————————————————
1 o7 p& U$ L5 M. z# w6 [$ {! {! B7 V: qCombination Feasibility according to preliminary data ! `% T" S/ n3 X
——————————————————————————————————
( t) w0 x/ l: T' Y5 I5 R4 jBevacizumab + sorafenib Yes, reduced dose
7 c$ F8 A7 l$ U- T; g" @1 LBevacizumab + sunitinib† No ) P* W7 |' b6 U' L1 @4 o) k
Bevacizumab + temsirolimus Yes ; }. G; P# {0 E) a
Bevacizumab + everolimus Yes 3 R& ~& h. c5 m5 h( g: l
Sorafenib + sunitinib ?
- Y. M2 P, e4 ~2 {0 fSorafenib + temsirolimus Yes, reduced dose P- L, V5 {/ o) E) P
Sorafenib + everolimus Yes, reduced dose 5 t, E+ L6 ]! i* D" V1 x
Sunitinib + temsirolimus† No
0 L8 _1 ^: n+ f' b, f3 p+ Z1 S1 ?+ dSunitinib + everolimus ? & w* z5 e& g: k' @# n! s* @3 r9 r7 v, f
Temsirolimus + everolimus ? ( y7 H: m3 `, a, N% F4 B2 u
————————————————————! s& ^- J. ~. H1 R7 s" r! T
†Led to US FDA warning.7 F4 H4 {- P; @1 ?
?: As yet unattempted combination.; s6 v1 b& @+ S9 Q; v
|
显身卡
7 f* C* [4 ^: ^ C! K
